Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrin-linked kinase expression increases with prostate tumor grade.

J R Graff1, J A Deddens, B W Konicek

  • 1Cancer Division, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. graff_jeremy@lilly.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.

Cancer gene therapy·2015
Same author

mGlu2/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2/3 receptor antagonism and its relation to antidepressant-like efficacy in mice.

CNS & neurological disorders drug targets·2013
Same author

Pre-death grief in Parkinson's caregivers: a pilot survey-based study.

Parkinsonism & related disorders·2012
Same author

Outcome evaluation of an intensive residential treatment program for bulimia.

The Journal of psychotherapy practice and research·2012
Same author

A revised SAS macro for maximum likelihood estimation of prevalence ratios using the COPY method.

Occupational and environmental medicine·2009
Same author

Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.

British journal of cancer·2008
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Integrin-linked kinase (ILK) expression significantly increases with prostate cancer progression and is linked to higher cell proliferation and poorer patient survival, implicating ILK in tumor advancement.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Integrin-linked kinase (ILK) overexpression is implicated in tumor progression, anoikis suppression, and invasion.
  • ILK inhibition in prostate adenocarcinoma (CaP) cells induces cell cycle arrest and apoptosis.
  • ILK expression escalates with androgen-independent CaP progression.

Purpose of the Study:

  • To investigate the correlation between ILK expression and the development and progression of prostate cancer.
  • To determine if ILK levels are associated with CaP aggressiveness and patient outcomes.

Main Methods:

  • Immunohistochemistry was employed to evaluate ILK expression in 100 human prostate tissue samples.
  • Analysis included comparisons between high-grade CaP, low-grade CaP, and benign prostatic hyperplasia.

Related Experiment Videos

Main Results:

  • ILK expression significantly increases with CaP progression, being higher in high-grade CaP than benign tissues.
  • Elevated ILK immunostaining correlates with increased proliferative index in CaP.
  • Intense ILK expression is inversely associated with 5-year patient survival.

Conclusions:

  • ILK expression dramatically rises with CaP progression.
  • Increased ILK is linked to the elevated proliferation driving CaP cell gain.
  • Enhanced ILK expression serves as a negative prognostic indicator for 5-year survival in prostate cancer patients.